Colorectal Cancer
Capecitabine and Celecoxib w/wo Radiation Therapy for Colorectal Cancer Patients Previously Treated With Fluorouracil (ADAPT - 7707)
A Phase II Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer
Investigator: Edward Lin, MD; Conditions: Recurrent Colon Cancer, Recurrent Rectal Cancer; Status: Recruiting; Study ID: NCT01729923
A Phase III Clinical Trial Evaluating TheraSphere® in Patients with Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy
Investigator: William Harris; Conditions: Colorectal Cancer; Status: Recruiting; Study ID: NCT01483027
Randomised Comparative Study Of Folfox6m Plus SIR-Spheres® Microspheres Versus Folfox6m Alone As First Line Treatment In Patients With Nonresectable Liver Metastases From Primary Colorectal Carcinoma
Investigator: Andrew Coveler, MD; Conditions: Colorectal Cancer, Colorectal Carcinoma, Liver Metastases; Status: Recruiting; Study ID: NCT00724503
A Randomized, Double-Blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab (Avastin), Oxaliplatin, and a Fluoropyrimidine
Investigator: Veena Shankaran; Conditions: Colon Cancer; Gastrointestinal Cancer; Rectal Cancer; Solid Tumors; Status: Recruiting; Study ID: NCT01183780
Statin Polyp Prevention Trial in Patients with Resected Colon Cancer
Investigator: Tanya Wahl, MD; Conditions: Colon Cancer; Status: Recruiting; Study ID: NCT01011478
A Phase 1 Study of ABT-888 (Veliparib) in Combination With Carboplatin (Paraplatin) and Gemcitabline (Gemzar) in Subjects With Advanced Solid Tumors
Investigator: Heidi J. Gray, MD; Conditions: Advanced Solid Tumors; Status: Closed; Study ID: NCT01063816
A Phase 1, Open-label, Dose-escalation, Multidose Study of MDX-1105 Administered Every 14 Days in Subjects With Selected Advanced or Recurrent Solid Tumors
Investigator: Scott S. Tykodi, MD, PhD; Conditions: Renal Cell Carcinoma, Non-small Cell Lung Cancer, Malignant Melanoma, Epithelial Ovarian Cancer; Status: Recruiting; Study ID: NCT00729664
Validation and Comparison of Biomarkers for the Early Detection of Colorectal Adenocarcinoma
Investigator: William M. Grady, MD; Conditions: Colon Cancer, Rectal Cancer; Status: Recruiting; Study ID: NCT01511653
A Phase 1b/2 Study With Gemcitabine and LY2157299 for Patients With Metastatic Cancer (Phase 1b) and Advanced or Metastatic Unresectable Pancreatic Cancer (Phase 2)
Investigator: Andrew Coveler, MD; Conditions: Neoplasms, Neoplasm Metastasis, Pancreatic Cancer; Status: Recruiting; Study ID: NCT01373164
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.
Investigator: Andrew Coveler, MD; Conditions: Colorectal Cancer; Status: Recruiting; Study ID: NCT01479465
A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects
Investigator: William P. Harris, MD; Conditions: Colorectal Cancer; Status: Recruiting; Study ID: NCT01478594
A Phase IIA Open Label, Adaptive, Randomized Clinical Trial of Dalotuzumab (MK-0646) Treatment in Combination with Irinotecan Versus Cetuximab and Irinotecan for Patients with Metastatic Rectal Cancers (mRC) Expressing High IGF-1/Low IGF-2 Levels
Investigator: Edward Lin, MD; Conditions: Colon Cancer; Rectal Cancer; Solid Tumors; Status: Recruiting; Study ID: NCT01609231
A Phase II, Multicenter, Open-Label, Randomized Study Evaluating The Efficacy And Safety Of Folfiri + Mehd7945a Versus Folfiri + Cetuximab In Second Line In Patients With Kras Wild-Type Metastatic Colorectal Cancer
Investigator: Andrew Coveler, MD; Conditions: Colorectal Cancer; Status: Recruiting; Study ID: NCT01652482
A Phase II/III Trial of Neoadjuvant FOLFOX, With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision
Investigator: Alessandro Fichera, MD; Conditions: Colorectal Cancer; Status: Recruiting; Study ID: NCT01515787
Join Us On